Effect of lipoxygenase inhibitor (nordihydroguaiaretic acid, NDGA) on canine pancreatic allografts. 1991

K Konishi, and T Watanabe, and K Yabushita, and H Hirosawa, and R Izumi, and I Miyazaki
Department of Surgery II, School of Medicine, Kanazawa University, Ishikawa, Japan.

UI MeSH Term Description Entries
D007328 Insulin A 51-amino acid pancreatic hormone that plays a major role in the regulation of glucose metabolism, directly by suppressing endogenous glucose production (GLYCOGENOLYSIS; GLUCONEOGENESIS) and indirectly by suppressing GLUCAGON secretion and LIPOLYSIS. Native insulin is a globular protein comprised of a zinc-coordinated hexamer. Each insulin monomer containing two chains, A (21 residues) and B (30 residues), linked by two disulfide bonds. Insulin is used as a drug to control insulin-dependent diabetes mellitus (DIABETES MELLITUS, TYPE 1). Iletin,Insulin A Chain,Insulin B Chain,Insulin, Regular,Novolin,Sodium Insulin,Soluble Insulin,Chain, Insulin B,Insulin, Sodium,Insulin, Soluble,Regular Insulin
D007975 Leukotriene B4 The major metabolite in neutrophil polymorphonuclear leukocytes. It stimulates polymorphonuclear cell function (degranulation, formation of oxygen-centered free radicals, arachidonic acid release, and metabolism). (From Dictionary of Prostaglandins and Related Compounds, 1990) 5,12-HETE,5,12-diHETE,LTB4,Leukotriene B,Leukotriene B-4,Leukotrienes B,5,12 HETE,5,12 diHETE,B-4, Leukotriene,Leukotriene B 4
D009637 Masoprocol A potent lipoxygenase inhibitor that interferes with arachidonic acid metabolism. The compound also inhibits formyltetrahydrofolate synthetase, carboxylesterase, and cyclooxygenase to a lesser extent. It also serves as an antioxidant in fats and oils. Nordihydroguaiaretic Acid,(R*,S*)-4,4'-(2,3-Dimethylbutane-1,4-diyl)bispyrocatechol,Actinex,Dihydronorguaiaretic Acid,Nordihydroguaiaretic Acid, (R*,S*)-Isomer,meso-Nordihydroguaiaretic Acid,Acid, meso-Nordihydroguaiaretic,meso Nordihydroguaiaretic Acid
D001786 Blood Glucose Glucose in blood. Blood Sugar,Glucose, Blood,Sugar, Blood
D004285 Dogs The domestic dog, Canis familiaris, comprising about 400 breeds, of the carnivore family CANIDAE. They are worldwide in distribution and live in association with people. (Walker's Mammals of the World, 5th ed, p1065) Canis familiaris,Dog
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D016035 Pancreas Transplantation The transference of a pancreas from one human or animal to another. Grafting, Pancreas,Transplantation, Pancreas,Graftings, Pancreas,Pancreas Grafting,Pancreas Graftings,Pancreas Transplantations,Transplantations, Pancreas
D016859 Lipoxygenase Inhibitors Compounds that bind to and inhibit that enzymatic activity of LIPOXYGENASES. Included under this category are inhibitors that are specific for lipoxygenase subtypes and act to reduce the production of LEUKOTRIENES. 5-Lipoxygenase Inhibitor,Lipoxygenase Inhibitor,12-Lipoxygenase Inhibitors,15-Lipoxygenase Inhibitors,5-Lipoxygenase Inhibitors,Arachidonate 12-Lipoxygenase Inhibitors,Arachidonate 15-Lipoxygenase Inhibitors,Arachidonate 5-Lipoxygenase Inhibitors,Inhibitors, Lipoxygenase,12 Lipoxygenase Inhibitors,12-Lipoxygenase Inhibitors, Arachidonate,15 Lipoxygenase Inhibitors,15-Lipoxygenase Inhibitors, Arachidonate,5 Lipoxygenase Inhibitor,5 Lipoxygenase Inhibitors,5-Lipoxygenase Inhibitors, Arachidonate,Arachidonate 12 Lipoxygenase Inhibitors,Arachidonate 15 Lipoxygenase Inhibitors,Arachidonate 5 Lipoxygenase Inhibitors,Inhibitor, 5-Lipoxygenase,Inhibitor, Lipoxygenase,Inhibitors, 12-Lipoxygenase,Inhibitors, 15-Lipoxygenase,Inhibitors, 5-Lipoxygenase,Inhibitors, Arachidonate 12-Lipoxygenase,Inhibitors, Arachidonate 15-Lipoxygenase,Inhibitors, Arachidonate 5-Lipoxygenase

Related Publications

K Konishi, and T Watanabe, and K Yabushita, and H Hirosawa, and R Izumi, and I Miyazaki
July 2007, Bioorganic & medicinal chemistry letters,
K Konishi, and T Watanabe, and K Yabushita, and H Hirosawa, and R Izumi, and I Miyazaki
September 1988, The British journal of dermatology,
K Konishi, and T Watanabe, and K Yabushita, and H Hirosawa, and R Izumi, and I Miyazaki
March 2006, Toxicology in vitro : an international journal published in association with BIBRA,
K Konishi, and T Watanabe, and K Yabushita, and H Hirosawa, and R Izumi, and I Miyazaki
January 2004, Life sciences,
K Konishi, and T Watanabe, and K Yabushita, and H Hirosawa, and R Izumi, and I Miyazaki
March 1984, Journal of biochemistry,
K Konishi, and T Watanabe, and K Yabushita, and H Hirosawa, and R Izumi, and I Miyazaki
May 2017, Chemico-biological interactions,
K Konishi, and T Watanabe, and K Yabushita, and H Hirosawa, and R Izumi, and I Miyazaki
February 2010, Journal of materials science. Materials in medicine,
K Konishi, and T Watanabe, and K Yabushita, and H Hirosawa, and R Izumi, and I Miyazaki
March 2005, Journal of cellular physiology,
K Konishi, and T Watanabe, and K Yabushita, and H Hirosawa, and R Izumi, and I Miyazaki
December 2001, Anti-cancer drug design,
K Konishi, and T Watanabe, and K Yabushita, and H Hirosawa, and R Izumi, and I Miyazaki
October 1984, Prostaglandins, leukotrienes, and medicine,
Copied contents to your clipboard!